A Deep Bench of Pharmaceutical Industry Expertise with a Proven Track Record

The Romeg team has extensive industry experience at start-up, private, and public pharmaceutical companies with a solid track record of licensing deals and successful company exits. The team has led over 20 product launches and 5 successful 505(b)(2) NDA approvals with FDA.

Our Team

Indu Muni, Ph.D. Founder & CEO

Prior to starting ROMEG Therapeutics, Dr. Muni founded CutisPharma in 1998 and served as the Company’s CEO until May 2015. Dr. Muni brings over 40 years of experience in the pharmaceutical industry, with a deep background in pharmacy and toxicology.

Previously, Dr. Muni served as the CEO of DynaGen, Inc., a publicly-held biotechnology company. Prior to DynaGen, Dr. Muni served in numerous senior level positions in the pharmaceutical, chemical and toxicology testing industries including BioAssay Systems, Inc., Miles Laboratories, and JT Baker. Dr. Muni has a Ph.D. in Pharmaceutical Sciences from the University of Mississippi.

Gita Muni, M.S., M.T. Co-Founder & Executive Vice President

Prior to co-founding ROMEG Therapeutics, Gita Muni helped found CutisPharma in 1998 and served as V.P. of Administration until May 2015. Prior to Cutis Pharma, she worked at DynaGen, Inc. helping to monitor clinical trials at various locations.

Additionally, she worked at the local hospitals as a medical technologist, (M.T.) Gita Muni holds a M.S. in pharmaceutical sciences from Bombay University, India, and she is also a registered medical technologist, (A.S.C.P.).

Naomi Vishnupad, Ph.D. Chief Scientific Officer

Dr. Vishnupad is an entrepreneurial scientific business executive with over 20 years of experience in inventing novel products and bringing new product technologies to the prescription and life sciences market.

She has served as the COO at Imaginative Research Associates, a dermatological product development company, for 20 years. Previously, Dr. Vishnupad held positions at Wyeth Pharmaceuticals and Bristol-Myers Squibb. She received a Ph.D. in Immunology from MCP-Hahnemann/Drexel University School of Medicine, a M.S. in Immunology from NYU, and a B.S. in Biology from Boston University.

Neal I. Muni, MD, MSPH Advisor

Dr. Muni has served for over 20 years in senior roles across the entire life sciences value chain, most recently serving as the CEO of Azurity Pharmaceuticals. In his role, Dr. Muni led two successful private equity transactions, including a company recapitalization and eventual successful company sale and exit. During his tenure, Dr. Muni led the transformation of the company from a virtually operated pharmacy distributor into a fully integrated specialty pharma, leading the acquisition of Silvergate Pharmaceuticals as well as overseeing the FDA approval and launch of two pipeline drugs, FIRVANQ® for clostridium dificile colitis and Katerzia® for pediatric hypertension.

James NagleConsultant, Commercial Operations and Logistics

With a 30-year history of demonstrable success in the Pharmaceutical and Distribution arena, Mr. Nagle is well suited to help tailor sales, marketing and operational strategies designed to leverage a company’s core competencies and intelligently capitalize on new business growth and market expansion opportunities. Prior to working with ROMEG Mr. Nagle was Senior Vice President of Commercial Operations at CutisPharma, his team successfully launched numerous Branded Pharmaceutical products during his tenure.